blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3200818

EP3200818 - METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.04.2023
Database last updated on 27.07.2024
FormerThe patent has been granted
Status updated on  06.05.2022
FormerGrant of patent is intended
Status updated on  23.11.2021
FormerExamination is in progress
Status updated on  02.11.2018
FormerRequest for examination was made
Status updated on  07.07.2017
FormerThe international publication has been made
Status updated on  28.04.2017
Most recent event   Tooltip31.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 03.07.2024  [2024/27]
Applicant(s)For all designated states
The United States of America, as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
National Institutes of Health
6701 Rockledge Drive, Suite 700
MSC 7788
Bethesda, MD 20892-7788 / US
[2022/19]
Former [2021/51]For all designated states
The United States of America, as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
MSC 7660
Bethesda, MD 20892-7660 / US
Former [2017/32]For all designated states
The U.S.A. as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
National Institutes of Health
6001 Executive Boulevard, Suite 325
MSC 7660
Bethesda, MD 20892-7660 / US
Inventor(s)01 / TRAN, Eric
5411 McGrath Blvd. Apt. 1212
North Bethesda, Maryland 20852 / US
02 / LU, Yong-Chen
1620 East Jefferson, Apt 111
Rockville, Maryland 20852 / US
03 / ROBBINS, Paul E.
7907 Glendale Road
Chevy Chase, Maryland 20815 / US
04 / ROSENBERG, Steven A.
10104 Iron Gate Road
Potomac, Maryland 20854 / US
 [2017/34]
Former [2017/32]01 / TRAN, Eric
5411 McGrath Blvd. Apt. 1212
North Bethesda, Maryland 20852 / US
02 / LU, Yong-Chen
1649 E Jefferson St. Apt. 202
Rockville, Maryland 20852 / US
03 / ROBBINS, Paul E.
7907 Glendale Road
Chevy Chase, Maryland 20815 / US
04 / ROSENBERG, Steven A.
10104 Iron Gate Road
Potomac, Maryland 20854 / US
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2022/23]Huenges, Martin
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2017/32]Huenges, Martin
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date14796317.702.10.2014
[2017/32]
WO2014US58796
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016053338
Date:07.04.2016
Language:EN
[2016/14]
Type: A1 Application with search report 
No.:EP3200818
Date:09.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 07.04.2016 takes the place of the publication of the European patent application.
[2017/32]
Type: B1 Patent specification 
No.:EP3200818
Date:08.06.2022
Language:EN
[2022/23]
Search report(s)International search report - published on:EP07.04.2016
ClassificationIPC:A61K39/00, C07K14/725, C07K14/47, C12N5/0783, A61P35/00, A61P35/02
[2021/47]
CPC:
C07K14/7051 (EP,CN,US); A61K39/0011 (US); A61K39/4611 (EP,CN);
A61K39/4632 (EP,CN); A61K39/464406 (EP,CN); A61P35/00 (EP);
A61P35/02 (EP); C12N5/0636 (EP,CN,US); C12N5/0638 (EP,CN,US);
C12Q1/6881 (US); G01N33/56977 (US); G01N33/6866 (US);
G01N33/6869 (US); A61K2039/5156 (US); A61K2039/5158 (US);
A61K2239/51 (EP,CN); A61K2239/52 (EP,CN); C12N2501/505 (EP,CN,US);
C12N2501/998 (US); C12N2502/99 (US); C12N2510/00 (EP,CN,US);
C12Q2600/156 (US); C12Q2600/158 (US); G01N2333/4725 (US);
G01N2333/525 (US); G01N2333/535 (US); G01N2333/54 (US);
G01N2333/5406 (US); G01N2333/5409 (US); G01N2333/5425 (US);
G01N2333/5428 (US); G01N2333/55 (US); G01N2333/57 (US);
G01N2333/70596 (US) (-)
Former IPC [2017/32]A61K39/00, C07K14/725, C07K14/47, C12N5/0783
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/32]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR ISOLIERUNG VON T-ZELL-REZEPTOREN MIT ANTIGENSPEZIFIZITÄT GEGEN EINE KREBSSPEZIFISCHE MUTATION[2017/32]
English:METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION[2017/32]
French:PROCÉDÉS D'ISOLEMENT DE RÉCEPTEURS DES LYMPHOCYTES T PRÉSENTANT UNE SPÉCIFICITÉ ANTIGÉNIQUE POUR UNE MUTATION SPÉCIFIQUE DU CANCER[2017/32]
Entry into regional phase28.04.2017National basic fee paid 
28.04.2017Designation fee(s) paid 
28.04.2017Examination fee paid 
Examination procedure28.04.2017Examination requested  [2017/32]
28.04.2017Date on which the examining division has become responsible
22.11.2017Amendment by applicant (claims and/or description)
06.11.2018Despatch of a communication from the examining division (Time limit: M06)
09.05.2019Reply to a communication from the examining division
04.06.2021Cancellation of oral proceeding that was planned for 10.06.2021
10.06.2021Date of oral proceedings (cancelled)
16.06.2021Despatch of a communication from the examining division (Time limit: M02)
17.08.2021Reply to a communication from the examining division
24.11.2021Communication of intention to grant the patent
31.03.2022Fee for grant paid
31.03.2022Fee for publishing/printing paid
31.03.2022Receipt of the translation of the claim(s)
Divisional application(s)EP22166152.3  / EP4074333
Opposition(s)10.03.2023No opposition filed within time limit [2023/20]
Fees paidRenewal fee
27.02.2017Renewal fee patent year 03
27.10.2017Renewal fee patent year 04
29.10.2018Renewal fee patent year 05
28.10.2019Renewal fee patent year 06
27.10.2020Renewal fee patent year 07
27.10.2021Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.10.2014
AL08.06.2022
AT08.06.2022
CY08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
MK08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IE02.10.2022
LU02.10.2022
IS08.10.2022
PT10.10.2022
[2024/27]
Former [2024/21]HU02.10.2014
AL08.06.2022
AT08.06.2022
CY08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IE02.10.2022
LU02.10.2022
IS08.10.2022
PT10.10.2022
Former [2024/18]HU02.10.2014
AL08.06.2022
AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IE02.10.2022
LU02.10.2022
IS08.10.2022
PT10.10.2022
Former [2023/48]AL08.06.2022
AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IE02.10.2022
LU02.10.2022
IS08.10.2022
PT10.10.2022
Former [2023/30]AL08.06.2022
AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
LU02.10.2022
IS08.10.2022
PT10.10.2022
Former [2023/25]AL08.06.2022
AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
MC08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SI08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/17]AL08.06.2022
AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/12]AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
IS08.10.2022
PT10.10.2022
Former [2023/11]AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
PL08.06.2022
RO08.06.2022
RS08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
PT10.10.2022
Former [2023/09]AT08.06.2022
CZ08.06.2022
EE08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
RO08.06.2022
RS08.06.2022
SK08.06.2022
SM08.06.2022
BG08.09.2022
GR09.09.2022
PT10.10.2022
Former [2023/07]AT08.06.2022
FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
RS08.06.2022
BG08.09.2022
GR09.09.2022
Former [2022/50]FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
RS08.06.2022
BG08.09.2022
GR09.09.2022
Former [2022/49]FI08.06.2022
HR08.06.2022
LT08.06.2022
LV08.06.2022
BG08.09.2022
GR09.09.2022
Former [2022/47]FI08.06.2022
LT08.06.2022
Cited inInternational search[XY]  - E TRAN ET AL, "Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer", SCIENCE, (20140508), vol. 344, no. 6184, doi:10.1126/science.1250498, ISSN 0036-8075, pages 641 - 645, XP055161453 [X] 1-14 * the whole document * [Y] 15-20

DOI:   http://dx.doi.org/10.1126/science.1251102
    [ ] - E. TRAN ET AL, "Supplementary Materials for Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer", SCIENCE, (20140508), vol. 344, no. 6184, doi:10.1126/science.1251102, ISSN 0036-8075, pages 641 - 645, XP055161464 [ ] * the whole document *

DOI:   http://dx.doi.org/10.1126/science.1251102
 [Y]  - ERIC TRAN ET AL, "T-cell therapy against cancer mutations", ONCOTARGET, (20140719), pages 4579 - 4580, XP055193038 [Y] 15-20 * the whole document *

DOI:   http://dx.doi.org/10.18632/oncotarget.2234
by applicantUS8034334
 US2012244133
 US8383099
    - ZHANG ET AL., J. GENET. GENOMICS, (2011), vol. 38, no. 3, pages 95 - 109
    - VOELKERDING ET AL., CLINICAL CHEMISTRY, (2009), vol. 55, pages 641 - 658
    - RONAGHI ET AL., SCIENCE, (1998), vol. 281, no. 5375, pages 363 - 365
    - TURCOTTE ET AL., CLIN. CANCER RES., (2013), vol. 20, no. 2, pages 331 - 43
    - GROS ET AL., J. CLIN. INVEST., (2014), vol. 124, no. 5, pages 2246 - 59
    - DUDLEY ET AL., J IMMUNOTHER., (2003), vol. 26, pages 332 - 42
    - RIDDELL ET AL., J IMMUNOL. METHODS, (1990), vol. 128, pages 189 - 201
    - JONES ET AL., SCIENCE, (2010), vol. 330, pages 228 - 231
    - JIN ET AL., J. IMMUNOTHER., (2012), vol. 35, pages 283 - 292
    - DUDLEY ET AL., J CLIN. ONCOL., (2008), vol. 26, pages 5233 - 9
    - DUDLEY ET AL., J. IMMUNOTHER., (2003), vol. 26, pages 332 - 42
    - RIDDELL ET AL., SCIENCE, (1992), vol. 257, pages 238 - 41
    - ROBBINS ET AL., NAT. MED., (2013), vol. 19, pages 747 - 52
    - JONES ET AL., SCIENCE, (2010), vol. 330, pages 228 - 31
    - HOOF ET AL., IMMUNOGENETICS, (2009), vol. 61, pages 1 - 13
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.